Phase Pilot

A Phase II Study of Lenvatinib in Combination With Pembrolizumab in HPV-associated Recurrent Respiratory Papillomatosis Patient

Volunteers
Health Professionals

What is the purpose of this trial?

This research study is studying Lenvatinib in combination with Pembrolizumab in people with human papillomavirus (HPV)-associated recurrent respiratory papillomatosis (RRP).

The names of the study drugs involved in this study are:

Pembrolizumab
Lenvatinib

Ages
18 years and older

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Anna Wu

anna.wu@yale.edu

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Sara Isabel Pai, MD, PhD
Professor

Sub-Investigators

Last Updated
11/19/2025
Study HIC
#2000035849